Professional Documents
Culture Documents
Global Autoimmune and Inflammatory Immunomodulators Market 2016-2020
Global Autoimmune and Inflammatory Immunomodulators Market 2016-2020
Price 1-user PDF : $ 2500.0 1-5 User PDF : $ 3000.0 Enterprise PDF : $ 10000.0
List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Different classes of immunosuppressant drugs based on their mechanism of action
Exhibit 03: Key buying criteria for global autoimmune and inflammatory immunomodulators market
2015
Exhibit 04: Key customer segments of autoimmune and inflammatory immunomodulators market
Exhibit 05: Etiology of autoimmune diseases
Exhibit 06: Pipeline portfolio: Rheumatoid arthritis immunomodulators
Exhibit 07: Pipeline portfolio: Ulcerative colitis immunomodulators
Exhibit 08: Pipeline portfolio: Crohn's disease immunomodulators
Exhibit 09: Global autoimmune and inflammatory immunomodulators market snapshot: Developed
and emerging markets 2015
Exhibit 10: Factors influencing global autoimmune and inflammatory immunomodulators market
Exhibit 11: Approval and patent expiries of top-selling biologics
Exhibit 12: Impact of factors affecting the market 2015 and 2020
Exhibit 13: Global autoimmune and inflammatory immunomodulators market 2015-2020 ($ billions)
Exhibit 14: Five forces analysis
Exhibit 15: Segmentation of global autoimmune and inflammatory immunomodulators by type of
disease based on revenue 2015
Exhibit 16: Global autoimmune and inflammatory immunomodulators market by disease type 2015-
2020
Exhibit 17: Global rheumatoid arthritis immunomodulators market 2015-2020 ($ billions)
Exhibit 18: Opportunities across rheumatoid arthritis industry
Exhibit 19: Global IBD immunomodulators market 2015-2020 ($ billions)
Exhibit 20: Global IBD therapeutics market segmentation growth lifecycle analysis
Exhibit 21: Global IBD immunomodulators market by disease type 2015-2020
Exhibit 22: Global ulcerative colitis immunomodulators market 2015-2020 ($ billions)
Exhibit 23: Global Crohn's disease immunomodulators market 2015-2020 ($ billions)
Exhibit 24: Comparative graph of global autoimmune and inflammatory immunomodulators market
by molecule type ($ billions)
Exhibit 25: Global autoimmune and inflammatory biologic immunomodulators market 2015-2020 ($
billions)
Exhibit 26: Biologicals approvals by the US FDA
Exhibit 27: Global rheumatoid arthritis biologic immunomodulators market 2015-2020 ($ billions)
Exhibit 28: Global IBD biologic immunomodulators market 2015-2020 ($ billions)
Exhibit 29: Global autoimmune and inflammatory small molecule immunomodulators market 2015-
2020 ($ billions)
Exhibit 30: Global autoimmune and inflammatory immunomodulators market by geography 2015-
2020
Exhibit 31: Global autoimmune and inflammatory immunomodulators market segmentation by
geography 2015-2020 ($ billions)
Exhibit 32: Global share of autoimmune and inflammatory immunomodulators market by geography
2015
Exhibit 33: Global autoimmune and inflammatory immunomodulators market segmentation by
region: Market growth lifecycle analysis 2015
Exhibit 34: Global autoimmune and inflammatory immunomodulators market: Country analysis
based on revenue and growth rate
Exhibit 35: Opportunity analysis of autoimmune and inflammatory immunomodulators market in
Americas
Exhibit 36: Autoimmune and inflammatory immunomodulators market in Americas 2015-2020 ($
billions)
Exhibit 37: Opportunity analysis of autoimmune and inflammatory immunomodulators market in
EMEA
Exhibit 38: Autoimmune and inflammatory immunomodulators market in EMEA 2015-2020 ($
billions)
Exhibit 39: Opportunity analysis of autoimmune and inflammatory immunomodulators market in
APAC
Exhibit 40: Autoimmune and inflammatory immunomodulators market in APAC 2015-2020 ($
billions)
Exhibit 41: Sales performance of key TNF-alpha inhibitors and B-cell inhibitors ($ billions)
Exhibit 42: Key vendors: Developing novel therapies
Exhibit 43: Key developments leading to improved diagnostics
Exhibit 44: Impact of drivers
Exhibit 45: List of few immunomodulators that were discontinued from development or market
Exhibit 46: CAM therapies for rheumatoid arthritis
Exhibit 47: Usage of CAM therapies in US adults
Exhibit 48: List of CAM therapies and items used in Crohn's disease and ulcerative colitis
Exhibit 49: List of adverse side effects associated with rheumatoid arthritis
Exhibit 50: Impact of drivers and challenges
Exhibit 51: Key marketed and pipeline oral agents
Exhibit 52: List of few biosimilars under development for various indications
Exhibit 53: List of few regenerative medicines under development for rheumatoid arthritis and IBD
Exhibit 54: Key deals in global immunomodulators market
Exhibit 55: Market share of key vendors 2015
Exhibit 56: Geographical presence of key vendors
Exhibit 57: Competitive scenario of global autoimmune and inflammatory immunomodulators
market vendors 2015-2020
Exhibit 58: AbbVie: Strength assessment
Exhibit 59: AbbVie: Strategy assessment
Exhibit 60: AbbVie: Opportunity assessment
Exhibit 61: AbbVie: YoY growth and revenue of Humira 2013-2015 ($ billions)
Exhibit 62: Johnson & Johnson: Strength assessment
Exhibit 63: Johnson & Johnson: Strategy assessment
Exhibit 64: Johnson & Johnson: Opportunity assessment
Exhibit 65: Johnson & Johnson: YoY revenue and growth rate of Remicade 2013-2015 ($ billions)
Exhibit 66: Johnson & Johnson: YoY revenue and growth rate of Simponi/Simponi Aria 2013-2015
($ billions)
Exhibit 67: Amgen: Strength assessment
Exhibit 68: Amgen: Strategy assessment
Exhibit 69: Amgen: Opportunity assessment
Exhibit 70: Amgen: YoY revenue and growth rate of Enbrel (in the US and Canada) 2013-2015 ($
billions)
Exhibit 71: F. Hoffmann-La Roche: Strength assessment
Exhibit 72: F. Hoffmann-La Roche: Strategy assessment
Exhibit 73: F. Hoffmann-La Roche: Opportunity assessment
Exhibit 74: F. Hoffmann-La Roche: YoY growth and revenue of MabThera/Rituxan for immunology
segment 2013-2015 ($ billions)
Exhibit 75: F. Hoffmann-La Roche: YoY growth and revenue of Actemra/RoActemra for
immunology segment 2013-2015 ($ billions)
Exhibit 76: Pfizer: Strength assessment
Exhibit 78: Pfizer: Strategy assessment
Exhibit 79: Pfizer: Opportunity assessment
Exhibit 80: Pfizer: Global autoimmune and inflammatory immunomodulators revenues 2014-2015 ($
billions)